Targeting the pathobiology of neutrophil extracellular traps

Citryll – a dutch biotech company – is taking a new approach to treat autoimmune and other human diseases like lupus, vasculitis, pulmonary fibrosis, asthma, rheumatoid arthritis and organ damage due to sepsis, by targeting and inhibiting the source of auto-antigens and neutrophil extracellular trap (NET) derived toxic molecules instead of broadly targeting inflammation or acquired immunity.

Scientific Approach

Citryll targets Neutrophil Extracellular Traps (NET) formation with a human antibody CIT-013 that interferes with the formation of NETs as well as promotes the clearance of NETs. A range of human diseases with potential for SLE, RA, vasculitis, asthma, IPF and other indications can be treated with CIT-013.

CIT-013 Development

A first human dosing will be done in 2021 as part of a Single Ascending Dose (SAD) study in healthy volunteers. GMP production and formulation of the antibody is being carried out by Citryll’s CMC partner Lonza and CTA enabling studies are being finalised in 2020.

Jobs at Citryll

Sorry, we couldn't find any posts. Please try a different search.

Latest News

Press release: Citryll Announces Dosing of the First Healthy Volunteer in a Phase 1 Clinical Trial for CIT-013, a First in Class Antagonist of NET Biology

Citryll’s first in class antibody drug candidate CIT-013 for autoimmune and chronic inflammatory diseases is beginning its bioanalytical phase at Ardena, a specialist pharmaceutical contract development and manufacturing organisation (CDMO).

Read More

Press release: Citryll enters into bioanalytics partnership with Ardena for the clinical development of CIT-013, antagonist of NET biology and associated pathologies

Citryll’s first in class antibody drug candidate CIT-013 for autoimmune and chronic inflammatory diseases is beginning its bioanalytical phase at Ardena, a specialist pharmaceutical contract development and manufacturing organisation (CDMO).

Read More

Latest News

Press release: Citryll Announces Dosing of the First Healthy Volunteer in a Phase 1 Clinical Trial for CIT-013, a First in Class Antagonist of NET Biology

Citryll’s first in class antibody drug candidate CIT-013 for autoimmune and chronic inflammatory diseases is beginning its bioanalytical phase at Ardena, a specialist pharmaceutical contract development and manufacturing organisation (CDMO).

Read More

Press release: Citryll enters into bioanalytics partnership with Ardena for the clinical development of CIT-013, antagonist of NET biology and associated pathologies

Citryll’s first in class antibody drug candidate CIT-013 for autoimmune and chronic inflammatory diseases is beginning its bioanalytical phase at Ardena, a specialist pharmaceutical contract development and manufacturing organisation (CDMO).

Read More

Press release: Citryll Appoints CTO and CSO

Citryll today announces it has appointed Eric Meldrum as Chief Scientific Officer and that current CSO and co-founder Renato Chirivi will transition into the role of Chief Technology Officer.

Read More